Proteomics: characterizing the cogs in the machinery of life. by Hood, Ernie
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question the very concept of the existence
of a measurable human proteome. Famed
genomicist J. Craig Venter put this doubt
succinctly when he told the 5 April 2001
Wall Street Journal that “there ain’t nosuch
thing as a proteome.”
Nevertheless, there can be no debate
that proteomics is poised to deliver vast
amounts of useful information about
physiologic function at the subcellular,
cellular, organic, and systemic levels, yield-
ing profound new insights into disease and
drug mechanisms, the effects of environ-
mental exposures, and much more.
Although a comprehensive map of the
entire human proteome may never be
accomplished, protein maps of human
organs, glands, and fluids and of entire
less-complex organisms are within sight,
and major efforts are under way to docu-
ment many of those proteomes.
Evolution of Proteomics
In large measure, proteomics has emerged
in parallel fashion with the other “-omics”
fields such as transcriptomics and metabo-
nomics. The technologies, methodologies,
and grand ambitions of the Human
Genome Project have rapidly proliferated
and now permeate virtually every area of
the life sciences. 
Just as the advent of genomics brought
the ability to discover large numbers of
genes quickly, proteomics was born when
technologic advances allowed scientists to
widen their focus from the painstaking iso-
lation and identification of single proteins
to a more comprehensive view of the entire
protein complement expressed in a given
cell line, tissue, or organism. However, pro-
teomics researchers employ their own
unique mix of tools, approaches, and skills
to address the questions they seek to
answer.
Although the term “proteomics” did
not exist until 1994, when Australian post-
doctoral student Marc Wilkins coined it,
the practice of the science has been going
on since the mid-1970s. Two milestone
technologic breakthroughs facilitated the
ability to look at multiplicities of proteins,
both of which, although much refined, are
still in wide use today in laboratories
around the world. 
At its core, proteomics is all about sep-
aration and identification—the process of
taking a sample of interest, separating out
all of the proteins therein, and then iden-
tifying them. The first major break-
through, which was a great leap forward in
separation, took place in 1975 with the
introduction of two-dimensional gel elec-
trophoresis (2DE). 
With this method—still the first step
in many proteomics experiments—pro-
teins from a sample are separated on a
polyacrylamide gel according to their mass
and charge, which, along with intensity,
are what provide the spectrum that makes
up a protein’s distinctive signature. The
more abundant the protein, the larger and
more intensely staining the spot on the gel. 
The only problem is that 2DE, while it
allows separation and visualization of the
protein complement, does little or nothing
to address identification. Regardless, the
advent of 2DE was so exciting that in 1980
it spawned the proposal of a Human
Protein Index project—an effort to catalog
all human proteins and then use that
knowledge to define the genome (although
Congress considered the project, it was
never funded, and advances in genomics
soon bypassed the idea).
The second major breakthrough, which
really brought proteomics into its own, was
the arrival of two crucial techniques in the
1980s that made possible the use of mass
spectrometry (MS) to identify proteins:
matrix-assisted laser desorption/ionization
(MALDI) and electrospray ionization
(ESI). These methods allow protein sam-
ples to be ionized for analysis in a mass
spectrometer, producing a pattern called a
mass spectrum. These mass spectra—
which often number in the thousands for
a given sample—can then be used to posi-
tively identify proteins or protein digests
(strings of peptides or protein fragments
produced when the proteins are ionized)
through the automatic querying of protein
databases. Unidentified or novel proteins
can be analyzed through further MS runs
or by other techniques. 
“ESI and MALDI were a quantum
leap,” says William Pierce, a professor of
pharmacology, toxicology, and chemistry
at the University of Louisville School of
Medicine. The subsequent development of
time-of-flight (TOF) detection, which
expanded the range of ionic molecular
weights detectable by MS instruments,
brought further analytic capabilities to
MALDI. Today, MALDI-TOF is in wide-
spread use in proteomics laboratories.
A dazzling panoply of MS refinements
and enhancements, as well as the develop-
ment of other technologies, now facilitate
the application of proteomic techniques to
a highly diversified universe of research
pursuits. Virtually every proteomics labo-
ratory, whether it’s connected with govern-
ment, academia, or industry, seems to have
its own favored technologic approach, and
many have developed their own in-house
methods, along with customized bioinfor-
matics software, to help sort through and
make sense of the massive amounts of data
their systems generate. 
“I think we need more than one plat-
form to be able to adequately do service to
measuring proteins in a global fashion,”
says B. Alex Merrick, head of the
Proteomics Group at the NIEHS National
Center for Toxicogenomics (NCT). “The
proteome is constantly changing. Tech-
nologically, you’re always trying to hit a
moving target.” Merrick cautions, howev-
er, that “because proteins have so many
properties, or attributes, and we have the
potential to measure them, it spawns
many, many platforms, and technological-
ly we haven’t sorted out which platforms
are the best ones.”
The general feeling among proteomics
researchers is that the field is on the verge
of consolidating years of method develop-
ment into a flood of knowledge. “I think
we’re about to transition out of the age of
explorers in proteomics to the age of appli-
cations,” says Daniel Liebler, a professor of
biochemistry and director of proteomics at
the Vanderbilt University School of
The proteome is constantly changing. Technologically, you’re
always trying to hit a moving target. 
— B. Alex Merrick
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Medicine. “Proteomics techniques are not
going to be done just as demonstrations of
powerful technology, but will really be
integrated into studies in basic laboratory
science, animal and nonanimal models of
diseases and environmental exposures, and
actually in human clinical studies as well.”
Proteomics in Action: Cancer
Detection
Thanks to progress in clinical proteomics,
someday soon a simple blood test could
hold the key to early diagnosis of certain
cancers. That is one of the many goals of
the Clinical Proteomics Program, a joint
research effort that is codirected by bio-
chemist Emanuel Petricoin of the U.S.
Food and Drug Administration (FDA)
and pathologist Lance Liotta of the
National Cancer Institute (NCI). 
The group has developed a method of
identifying protein patterns in blood
serum that is potentially indicative of the
presence of a wide range of diseases. Their
initial study, published 16 February 2002
in The Lancet, focused on ovarian cancer,
which presently has both a poor late-stage
survival rate and a poor early detection
rate—a deadly combination fostering an
urgent need for better diagnostic tests,
especially for women at high risk for
developing the disease.
The investigators used surface-
enhanced laser desorption/ionization TOF
(SELDI-TOF), a variation on MALDI-
TOF that incorporates protein microar-
rays and is particularly well suited to
detecting patterns of proteins in samples.
First, a “training” set of known, unblinded
samples was run through the instru-
ment—in this case, serum samples from
both healthy women and women with
ovarian cancer. With the high throughput
of the equipment, spectra for each sam-
ple—each one containing 15,200 data
points, or individual pieces of informa-
tion—were quickly generated. 
Next, the raw data were processed by a
unique bioinformatics system that incor-
porates a form of artificial intelligence
called a genetic algorithm. The genetic
algorithm compares the patterns of pro-
tein expression in the diseased samples to
those in the healthy samples, looking for
those patterns that optimally discriminate
between the two. The algorithm learns as
it goes in a process that involves hundreds
of millions of pattern combinations and
comparisons. The end product is a pattern
of unidentified proteins—in this case,
five—that precisely distinguishes healthy
samples from diseased ones. 
The next step was to run a set of
known but blinded samples through the
same process, and then compare the
results to assess the predictive power of the
patterns. In this study, the investigators
achieved a sensitivity of 100%—that is, all
of the cancerous samples were correctly
identified, with no false negatives—and a
specificity of 95%, meaning only 5% of
the identifications were false positive. This
was vastly superior to the 35% positive
predictive value in the same samples of
cancer antigen 125, the present gold stan-
dard clinical biomarker. 
Subsequent technical refinements
(which included a switch to a much high-
er-resolution and more stable mass spec-
trometer, and incorporation of advanced
spectral quality control methods) have
improved the system’s sensitivity and
specificity to 100% in a larger blinded set
of ovarian cancer and high-risk samples.
The team is currently enrolling partici-
pants in a clinical trial to test their
methodology in detecting recurrence of
ovarian cancer. 
Although the proteins in the discrim-
inatory pattern generated by this method
are at least initially unidentified, Petricoin
says that is beside the point. “We as sci-
entists want to understand what the
nature of the beast is, and we’re hunting
that down,” he says. “We’re already mak-
ing great progress to that end. But we
don’t see identity as necessary for its use in
diagnostics.”
Two of the world’s largest reference
laboratory companies apparently agree.
Quest Diagnostics and LabCorp have
sublicensed the technology from
Correlogic Systems (which developed the
initial genetics algorithm and licensed the
technology from the U.S. government),
and plan to start offering the proteomic
test as an ovarian cancer screening tool for
women at high risk by the end of 2003.
Initially, they will market the procedure
under the FDA’s “home brew” provision,
which allows the companies to perform
the service only in their own validated
laboratories. 
Petricoin is optimistic that proteomic
pattern diagnostics could impact medical
diagnostics in a big way. “This is a differ-
ent type of diagnostic paradigm,” he says.
“[It] completely changes and turns on its
head the normal tried-and-true route—
which we would suggest is failing—of
looking at discovery biomarkers. . . . I
think if either our or LabCorp/Quest’s
efforts are successful, it’s really going to
throw a gauntlet down on a completely
different type of diagnostic procedure
being used in the clinic. That could have
reverberations throughout disease detec-
tion, period.”
The FDA/NCI group is applying this
proteomic technique in similar studies of
breast, lung, pancreatic, esophageal, brain,
and prostate cancers, as well as efforts to
detect cancer drug cardiovascular toxicity
before symptoms occur, and to assess the
effectiveness of molecularly targeted can-
cer drugs. 
Another Approach: Cancer
Profiling
The Mass Spectrometry Research Center
at the Vanderbilt University School of
Proteomics techniques are not going to be done just as demon-
strations of powerful technology, but will really be integrated
into studies in basic laboratory science, animal and nonanimal
models of diseases and environmental exposures, and actually in
human clinical studies as well.
—Daniel Liebler
Vanderbilt University School of MedicineFocus | Proteomics
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Medicine, headed by Richard Caprioli,
the Stanley Cohen Professor of Bio-
chemistry, also is pursuing methods of dis-
tinguishing diseased tissue from healthy
tissue, particularly in cancer. But Cap-
rioli’s group takes a very different
approach, in which identification of the
proteins in the affected tissues themselves,
rather than in plasma, is central. It’s called
tissue proteome profiling, and it appears
to be a powerful new tool for both diag-
nosis and prognosis. 
Tissue proteome profiling has several
advantages, including the ability to accu-
rately detect factors such as life expectancy
and tumor aggressiveness. Tissue pro-
teome profiling could also directly identi-
fy potential targets for drug intervention,
as well as contribute to understanding of
mechanisms of the disease.
In their most complete study to date,
published 9 August 2003 in The Lancet,
Caprioli and his coworkers concentrated
on lung tumors. They took hundreds of
lung tumor biopsy samples and analyzed
their protein complements via MALDI
MS, looking at several spots on each sam-
ple, each of which generated thousands of
signals in a specific pattern of proteins.
Then, using a series of bioinformatics
tools, they correlated the tissue proteome
profiling information with known infor-
mation about the individual patients,
some of whom had already died of their
disease. 
“We found that at the first level, we
could find unique sweeps of proteins that
helped us actually classify the disease,”
says Caprioli. “So if you take the biggest
set of lung tumors, non–small cell lung
carcinomas, we could further classify them
as adenocarcinomas, squamous cell carci-
nomas, and so on.” 
Of  course, pathologists can do the
same, but Caprioli says they didn’t stop
there. “We asked, ‘Can we correlate these
patterns with the life expectancy or the
prognostic value of these diseases?’ And it
turned out to be of very high accuracy.”
He says the researchers could tell from the
protein pattern which patients would go
on to survive for long periods of time, and
which patients would die of cancer—“so
the aggressiveness of the disease was
apparent in the protein profile.” 
They were further able to pick out
with approximately 80% accuracy those
patients whose tumors had metastasized,
causing nodal involvement and the often
inoperable development of secondary
tumors. There is presently no other
method of making such a crucial clinical
prediction. 
Although appropriately cautious to
point out that these results were in just
one type of tumor study, Caprioli is excit-
ed about the possibility of using protein
patterns to identify types of tumors that
have an aggressive posture for nodal
involvement. “It begins to get you out of
just diagnosing to actual patient care, so
that the clinician can now identify a high-
risk group and make the appropriate ther-
apeutic decisions,” he says.
Caprioli’s group is nearing completion
of a similar study of brain tumors with
similar results in terms of the power of tis-
sue protein profiling for prognostication.
They’re also looking at diabetes mellitus,
cardiac and pulmonary diseases, and sever-
al other conditions. Caprioli asserts that
this platform, along with other clinical
proteomics work, ultimately constitutes
an entry point into the field of individual-
ized medicine, centered around the con-
cept that each patient’s disease is unique at
the molecular level. “It’s a whole new way
of looking at things,” he says. “There’s no
doubt in my mind that as we collectively
learn more and more about the molecular
ways of diagnosing disease, of predicting
disease progression, that this individual-
ized way of looking at diseases will become
more and more common.”
Toxicoproteomics: Mechanisms and
Biomarkers
Liebler’s main focus is toxicoproteomics.
His group concentrates on understanding
how reactive intermediates produce dele-
terious effects by modifying proteins.
These unstable chemical species enter a
cell as a result of environmental exposures
and tend to bind to proteins or DNA,
modifying their properties in an injurious
way and forming new biomolecules
known as adducts. 
Using a form of MS called tandem
MS, or MS/MS, along with a novel algo-
rithm and proprietary bioinformatics soft-
ware called Scoring Algorithm for Spectral
Analysis, Liebler and his group are able to
analyze the mass spectra of peptides to
establish their sequences, the positions of
any modifications, and, by mapping that
information back onto the entire protein
sequence, the sites of modification in the
protein itself. Ultimately, two major ques-
tions are addressed: What are the protein
targets of reactive intermediates? And
what are the cellular responses to protein
modification? 
Answers to these questions will shed
light on some of the most important
avenues of contemporary research in toxi-
cology. Liebler sees the biggest near-term
payoff of this type of work as coming in
two general areas. One area is the under-
standing of mechanisms of toxicity. The
other is the identification of biomarkers of
exposure. “If we can figure out what the
targets of some of these environmental
compounds are or what reactive interme-
diates come from environmental stimuli
or stresses, by understanding mechanisms
we  then know what components of the
cell or tissues might be amenable to some
kind of protective intervention,” he says. 
As proof of principle, Liebler’s team
published a study in the June 2002 issue
of Chemical Research in Toxicology docu-
menting their system’s ability to map
hemoglobin adducts of the aliphatic
epoxides, a group of common industrial
chemicals. The team is most interested in
investigating biomarkers of oxidative
stress, the damaging phenomenon impli-
cated in many disease processes and often
the result of environmental exposure.
“What we would like to do is identify
some of the most abundant of these reac-
tive intermediates that are formed under
representative conditions either in vitro or
in animal models in vivo, where we can
manipulate oxidative stress,” says Liebler.
Pierce’s biomolecular MS lab at
Louisville is involved in similar functional
proteomics work. His group looks at sub-
sets, or small clusters, of functionally
interactive proteins. They isolate post-
translational modifications, any of more
than 100 different types of changes that
can be made to proteins by a variety of fac-
tors after their original creation. (This par-
tially accounts for the vastly larger number
of proteins than genes.) Pierce’s group also
works to develop or validate biomarkers in
cases of specific environmental or xenobi-
otic exposures and those agents’ interac-
tions with nucleic acids and proteins.
In a collaboration with Louisville pro-
fessor of medicine Aruni Bhatnagar, Pierce
and colleagues are looking at a very large,
ubiquitous set of chemicals, the aldehydes,
which form adducts with proteins, poten-
tially contributing to cardiovascular dis-
ease. Aldehydes are not just environmental
contaminants, but are also naturally pres-
ent in food and are intermediates in
human metabolism. By identifying alde-
hyde-induced adducts and elucidating
how they might influence protein func-
tion, the team hopes to characterize a
novel mechanism involved in hyperten-
sion, stroke, and other forms of cardiovas-
cular disease.
Pierce is also working on a project
with university associate professor of med-
icine James Summersgill, investigating theFocus | Proteomics
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Groups and Initiatives
Human Proteome Organisation (HUPO)
http://www.hupo.org/
An international research consortium intended to encourage large-scale
analysis of the human proteome 
Human Proteomics Initiative
http://www.expasy.org/sprot/hpi/
Joint effort of the Swiss Institute of Bioinformatics and the European
Bioinformatics Institute that seeks to comprehensively annotate all known
human proteins
National Heart, Lung, and Blood Institute Proteomics Initiative
A seven-year, $157 million program to accelerate the development of
innovative technologies to characterize healthy and diseased heart, lung,
blood, and sleep processes in 10 special centers of proteomics research
across the country
Protein Structure Initiative
http://www.structuralgenomics.org/
A 10-year project funded by the National Institute of General Medical
Sciences to determine the three-dimensional structures of 10,000 unique
proteins, while dramatically reducing the time and costs involved in
the process
Databases
Biomolecular Interaction Network Database
http://www.blueprint.org/
A comprehensive, publicly accessible repository administered by blueprint
WORLDWIDE for data and software tools related to critical biomolecular
functions
Chemical Effects in Biological Systems Knowledge Base
http://www.niehs.nih.gov/nct/cebs.htm
National Center for Toxicogenomics database that will exhaustively document
the toxic effects of chemicals in the environment and be fully searchable by
compound, structure, toxicity, pathology, gene, gene group, single-nucleotide
polymorphism, pathway, and network
Human Protein Reference Database
http://www.hprd.org/
Joint project of The Johns Hopkins University and the Institute of
Bioinformatics that is expected to eventually contain comprehensive
entries on 10,000 human proteins, including domain architecture, post-
translational modifications, interaction networks, and disease associations
Protein Sequence Database
http://pir.georgetown.edu/pirwww/dbinfo/pirpsd.html
A comprehensive annotated protein sequence database in the public
domain, maintained by the Protein Information Resource, that contained
more than 283,000 entries as of November 2003
Swiss-Prot
http://us.expasy.org/sprot/
A curated protein sequence database developed by the Swiss Institute of
Bioinformatics and the European Bioinformatics Institute that strives to
provide a high level of annotation, a minimal level of redundancy, and
high level of integration with other databases
TrEMBL
http://www.ebi.ac.uk/trembl/
A database maintained by the European Bioinformatics Institute that
contains the translations of all coding sequences present in the European
Molecular Biology Laboratory’s Nucleotide Sequence Database that are
not yet integrated into Swiss-Prot
United Protein Database
http://www.uniprot.org/
With $15 million in funding from six NIH institutes and centers, will combine
the resources of Swiss-Prot, TrEMBL, and the Protein Sequence Database.
Proteomics ResourcesFocus | Proteomics
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Pieces of the Proteomics Puzzle
Proteomics encompasses several different subdisciplines, each with its own unique
approach and its own contribution to the overall quest to glean knowledge from
the proteome.
Expression Proteomics
In expression (or profiling) proteomics, researchers seek to discover and quantify sig-
nificant differences in the totality of expressed proteins between known samples—
often diseased versus nondiseased or exposed versus unexposed. These differences
appear as patterns that can have a very high degree of predictive power, whether the
proteins in the pattern are identified (as some experts contend is necessary) or
remain unidentified (which others argue is sufficient). Expression proteomics studies
yield hypotheses that are then confirmed or refuted by other methods. Clinical pro-
teomics investigations, which seek to apply proteomics knowledge directly to med-
ical practice, typically employ expression proteomics methods.
Functional Proteomics
Functional proteomics encompasses a wide variety of studies involving sub-
sets of proteins. These studies seek to analyze and characterize specific
functions, including signaling pathways, interactions, disease mechanisms,
and biomarkers of disease or environmental exposures. In this field,
hypotheses are tested rather than developed, and protein identification is
vital to success.
Structural Proteomics
Structural proteomics concentrates on mapping the structure of
protein complexes or those proteins present in a specific cellular
organelle. Such information can provide valuable insights into cel-
lular architecture, which greatly influences cellular function. X-ray
crystallography and structural modeling by computational biology
are the main methods utilized to unravel these extremely compli-
cated systems.
Toxicoproteomics
In toxicoproteomics, the full range of proteomics methods and technologies are used in efforts
to uncover the cellular and subcellular mechanisms at work in response to xenobiotic expo-
sures. Researchers in this area are particularly interested in discovering biomarkers of exposure.Focus | Proteomics
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interactions of the microorganism
Chlamydia pneumoniae with the cardiovas-
cular system. Just as Helicobacter pylori has
been implicated in gastric ulcers, there is a
theory that microorganisms in the cardio-
vascular system could cause systemic
infection, leading to plaque development
and atherosclerosis. “We study the
chlamydial proteome and look at changes
in it and how that might be reflected in
the production of products that then stim-
ulate atherosclerotic lesions,” says Pierce. 
Like all proteomics practitioners, he is
enthusiastic about the possibilities that lie
ahead in the field. “The infinite variety of
states of proteins in the cell will give us the
opportunity, more so than in genomics, to
uncover new mechanisms in biology,” he
says. “In certain aspects you’re looking at a
dynamic system that is growing and
changing, and we can actually ‘catch biol-
ogy happening.’ And because of that, we’ll
find new mechanisms and be more likely
to develop new ways to look at mecha-
nisms or affect them.”
NIEHS researchers are also delving
into the field of proteomics. Merrick and
the NCT Proteomics Group, working in
partnership with Kenneth
B. Tomer, who heads
the NCT Mass Spec-
trometry Group, aid
the center’s efforts to
discover more and
better information
about the adverse ef-
fects of chemicals and
toxic compounds. Mer-
rick’s group works mainly
in expression proteomics
experiments with animals. “We want to be
able to evaluate the effects of chemicals in
experimental animals under the most con-
trolled conditions possible,” he says, “so
that we can separate out the true
effects of the chemicals from the
nonspecific ‘noise’ effects that
you always see with these types
of technologies.” 
Among other projects,
Merrick’s group uses SELDI to
examine the mechanisms of
action of two key proteins
involved in cell growth and cell
death—p53 and NFκB. “p53 is
often regarded as one of the ‘master
switches’ of life and death and cell growth
within the cell,” says Merrick. “In the
same sense, NFκB is a ‘master switch’ for
inflammation and immune response. In
these two proteins, we’re looking for spe-
cific markers, specific states that would
distinguish them in terms of their being
activated or deactivated in association
with a particular disease state or state of
cellular function.” 
In  the 3 April 2001 issue of Bio-
chemistry, the Merrick and Tomer groups
reported the results of their MS research
on p53. They were able to isolate the
entire protein from the cell for compre-
hensive MS analysis for the first time, in
an effort to shed light on how the fine
structure of the protein influences its abil-
ity to control cellular life and death. It has
long been suspected that phosphorylation,
a type of post-translational modification,
may be involved in the process. The group
discovered six specific phosphorylation
sites on the protein, one of which,
Ser(315), was particularly phosphorylated.
Unraveling the mystery of how p53 exerts
its “master switch” control over cellular
mortality would be an important advance
in biology, and this study constitutes a
major step toward that discovery.
The group is also undertaking a num-
ber of clinical projects in neurodegenera-
tive disease and cancer, taking advantage
of access to blood and serum samples
from NIEHS epidemiologic activities.
Serum proteomic analysis has much to
tell, according to Merrick. “The soluble
proteins within serum or plasma can be
reflective of a disease state, or of toxicity
or injury to a particular disease site,
whether it be in heart disease or liver dis-
ease,” he explains. “So proteomics can
shine in analysis of serum or plasma
because of the nature of disease, in that
you may either have release of a biomark-
er from a particular organ, or there may
be indications of a repair process going on
with serum or plasma that you can [detect
in the bodily fluids].” 
Toxicoproteomics can also be used to
discover previously unknown sites within
the cell, says Merrick. “When you’re deal-
ing with proteins, you’re dealing with
time and space,” he says. “These proteins
occupy a certain amount of space within
tissues or cells, and to be able to isolate
these subcellular portions that are impor-
tant targets of either therapy or of toxici-
ty is an area where proteomics can make a
special contribution.”
Calcium, Oxidation, and Aging
At  the Pacific Northwest National
Laboratory in Richland, Washington,
researcher Thomas Squier practices pro-
teomics as part of the laboratory’s systems
biology approach, which integrates infor-
mation from all of the -omics disciplines
to first determine how a cell functions and
then develop predictive models. The lab’s
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Biomolecular Systems Initiative, which
includes its proteomics work, is part of the
U.S. Department of Energy’s Genomes to
Life program, which aims at uncovering
biologic solutions for major environmen-
tal issues such as clean energy production,
removal of excess carbon dioxide from the
atmosphere, and remediation of contami-
nated environments. 
Squier’s group concentrates on analyz-
ing calcium regulation in cells and how
oxidative stress can trigger adaptive mech-
anisms, resulting in post-translational
modifications to key calcium sensor pro-
teins. Calcium maintains a 10,000-fold
gradient in cellular systems and is the key
player in the signaling that modulates
energy metabolism. Changing calcium
levels are responsible for much of the
cell’s sensing of the environment. By
identifying post-translational modifica-
tions of the key calcium sensor proteins
(changes such as methionine oxidation
and protein nitration), potentially impor-
tant new biomarkers of exposure can be
isolated. For example, the lab has identi-
fied the calcium signaling protein
calmodulin as a major target of oxidative
stress, as described in the January 2003
issue of Chemical Research in Toxicology.
This discovery could contribute signifi-
cantly to understanding of adaptive cellu-
lar responses to environmental exposures,
particularly in how repair and mainte-
nance systems are triggered.
Aging is an important factor in cellu-
lar adaptive ability as well. Aging is a
major risk factor for most diseases and for
sensitivity to environmental exposures,
says Squier. “In aging,” he says, “the key
regulatory proteins get oxidized, and their
oxidation slows metabolism down. We
speculate that this is an adaptive mecha-
nism to maintain this balance between
reactive species and cell function.” 
Ultimately, this work on the detection
of post-translational modifications of key
sensor proteins could lead to the develop-
ment of microarray-based assays that
would rapidly analyze a person’s antioxi-
dant status. In terms of applications,
Squier says, being able to quickly identify
changes in protein expression and discern
what post-translational modifications
happen is going to provide a very high
level of information about the health of an
individual, which in turn could lead to
greatly enhanced medical treatment. 
Proteomics Initiatives and
Databases
Considering the enormous challenges and
opportunities posed by proteomics, it’s
unsurprising that there are several collab-
orative proteomics initiatives under way
at the national and international levels.
Perhaps the best known of these cam-
paigns is the Human Proteome Organ-
isation (HUPO), an international body
intended to encourage large-scale analysis
of the human proteome. HUPO seeks to
consolidate national and regional pro-
teome organizations into a worldwide
research consortium. “Proteomics cannot
be fully grasped and developed without a
major international organized effort,
which HUPO intends to facilitate,” says
Samir Hanash, the organization’s presi-
dent and a professor of pediatrics at the
University of Michigan. 
HUPO has established a goal of map-
ping 5,000 human proteins, and is coor-
dinating and standardizing research in a
variety of pertinent areas. Its major proj-
ects include analysis of specific regions of
the body—the Human Plasma Proteome
Project, the Human Liver Proteome
Project, and the Human Brain Proteome
Project. Another major project is the
Proteomics Standards Initiative, which
aims to define community standards for
presentation of proteomics data. Still
other projects include initiatives involv-
ing new proteomics technologies, cell
models and tissue, bioinformatics, and
the development of a collection of stan-
dardized, high-quality antibodies for
every human protein. HUPO’s shared
resources, data, and establishment of
standardized protocols and reporting
guidelines should contribute substantially
to the understanding of disease processes
and chemical exposures.
The Human Proteomics Initiative
seeks to comprehensively annotate all
known human proteins, which means
parsing out each protein’s function,
domain structure, subcellular location,
post-translational modifications, variants,
similarities to other proteins, and protein
sequence polymorphisms. This ambitious
project is sponsored by the Swiss Institute
of Bioinformatics and the European
Bioinformatics Institute, the keepers of
one of the most widely used protein
sequence databases, Swiss-Prot.
Virtually all proteomics experiments
involve accessing and querying protein
databases as an integral step in the
process, allowing the identification and
characterization of detected proteins and
peptides. That vital link between data and
knowledge should be greatly enhanced by
the establishment of the United Protein
Database, or UniProt. Funded in October
2002 by a three-year, $15 million grant
subsidized primarily by the National
Human Genome Research Institute along
with five other institutes and centers of
the NIH, UniProt will combine the
resources of Swiss-Prot and two other
major annotated protein databases, the
European Bioinformatics Institute’s
TrEMBL and the Protein Information
Resource’s Protein Sequence Database. By
January 2005, UniProt will be fully oper-
ational and available to all users free of
charge.
In the world of proteomics, the main
action often centers around interactions,
molecular complexes, and pathways. The
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In certain aspects you’re looking at a dynamic system that is
growing and changing, and we can actually ‘catch biology hap-
pening.’ And because of that, we’ll find new mechanisms and be
more likely to develop new ways to look at mechanisms or affect
them.
—William Pierce
University of Louisville School of MedicineFocus | Proteomics
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Biomolecular Interaction Network
Database serves as a comprehensive, pub-
licly accessible repository for data and
software tools related to those critical bio-
molecular functions. The database is
administered by blueprint WORLD-
WIDE, a nonprofit organization
cofounded for that purpose by IBM and
MDS Proteomics of Toronto, Canada. 
Another important resource in the
protein database arena has recently been
launched as a joint project between
researchers at The Johns Hopkins
University in Baltimore, Maryland, and
the Institute of Bioinformatics in
Bangalore, India. By the end of 2003, the
Human Protein Reference Database is
expected to contain comprehensive
entries on 10,000 human proteins,
including domain architecture, post-
translational modifications, interaction
networks, and disease associations. The
information in this database has been
manually extracted from the literature by
biologists who read, interpret, and ana-
lyze the published data.
To  spur the progress of clinical pro-
teomics, in 2002 the National Heart,
Lung, and Blood Institute launched a
major initiative that created 10 special
centers of proteomics research at academ-
ic institutions across the country. The
seven-year, $157 million program is
designed to accelerate the development of
innovative technologies to characterize
healthy and diseased heart, lung, blood,
and sleep processes. Says the institute’s
proteomic program administrator Susan
Old, “This should speed the delivery of
potential new clinical applications from
research into practice.” The centers will
investigate protein profiling, interactions,
and post-translational modifications as
they relate to a variety of conditions,
including cardiovascular disease, autoim-
mune disease, airway inflammation, and
cystic fibrosis.
The development of better tools and
better knowledge of structural proteomics
is the goal of the Protein Structure
Initiative, a 10-year project funded by the
National Institute of General Medical
Sciences and launched in 2000 with an
open-ended budget. Currently in its pilot
phase, the initiative aims to determine the
three-dimensional structure of 10,000
unique proteins, while dramatically
reducing the time and costs involved in
the process. By 2005, each of nine centers
is expected to be able solve the structure
of 100–200 proteins annually. By group-
ing proteins into structural families, “the
initiative will develop a catalog of all the
protein structures that exist in nature,”
said Marvin Cassman, then director of
the National Institute of General Medical
Sciences, at the time the initiative was
launched. “We expect that it will yield
major biological findings that will
improve our understanding of health and
disease.”
Proteomics data are also expected to
play a large role in the Chemical Effects
in Biological Systems (CEBS) knowledge
base being developed by the NCT. CEBS
is designed to exhaustively document the
toxic effects of chemicals in the environ-
ment and will be fully searchable by com-
pound, structure, toxicity, pathology,
gene, gene group, single-nucleotide poly-
morphism, pathway, and network. The
knowledge base will be accessible by the
public, and will be a major contributor to
progress in the fields of toxicoproteomics
and toxicogenomics.
Proteomics Prognostications
Scratch your average proteomics investi-
gator and you will reveal an optimist just
under the sober scientific surface. The
excitement is palpable; the visions are
grand. But all in the field agree that for
proteomics to fulfill its lofty promise, cer-
tain key developments must take place,
several of which are well on their way to
fruition.
Technologic progress must continue
and accelerate. Many in the field are anx-
ious to see the replacement of the notori-
ously laborious 2DE method of protein
separation with a more automated, high-
throughput approach, such as antibody
microarrays or isotope-coded affinity tags.
All wish for further improvements and
refinements in MS equipment and bioin-
formatics, as well as development of other
technologies that could contribute to
progress in the field. 
“I think MS is becoming increasingly
powerful, and we haven’t yet realized the
full power of these tools,” says Liebler.
“On the other hand, I think MS-based
proteome analyses will give way to other
kinds of less high-tech approaches, using
perhaps some variants of array technolo-
gies: arrays of antibodies or aptamers
[basic nucleic acid equivalents of antibod-
ies] and perhaps small molecules that rec-
ognize proteins—little lab-on-a-chip
devices that would be suitable for analysis
of some components of proteins.” There
are a lot of competing technologies, he
says, and it’s hard to say what’s going to
work—“but if the last ten years have
taught us anything, it’s that we should be
prepared to be surprised, regularly.”
Philosophically, practitioners are con-
fident that the knowledge gleaned from
proteomics will ultimately converge and
integrate with advances in the other -
omics fields to evolve into a more holistic
systems biology discipline with the ability
to understand the processes and mecha-
nisms of life in a truly global fashion. “We
tend to think of ourselves as proteomics
people, or genomics people, or lipids peo-
ple, and in fact the cell and tissue only
exist because all of these things are inte-
grated,” says Caprioli. “How these things
all relate to one another is what’s going to
give us the key [to a more comprehensive
understanding of systems biology].”
Researchers believe that proteomics
will begin to make a tangible difference in
medicine and environmental health quite
soon. Merrick, for example, believes that
within five years, there will be perhaps
two or three key public databases that will
offer access to gene and protein expres-
sion experiments that are done in a stan-
dardized way, and researchers will be able
to query those databases for use in pre-
dicting human health responses to various
environmental interactions. In 10 years,
he says, “I believe that proteomics will be
able to go right into the clinic, in terms of
diagnostics and evaluation of blood and
serum in a way that clinical chemistry
can’t approach or compete with. Typically,
when you get blood drawn, you get
maybe twenty or thirty analyses. . . . I
think in the future this will just be
dwarfed by the amount of useful informa-
tion that will be derived at the proteomic
level.”
Petricoin is even less guardedly opti-
mistic. He predicts that in five years “a
patient will be able to have a pathophysi-
ological portrait performed by high-
throughput protein-based technologies
that can read out hundreds of thousands
of end points at once, and be able to pro-
vide the clinician a snapshot of what’s
going on in that organism.” Within a
decade, he says, will come the develop-
ment of high-throughput proteomics
coupled with artificial intelligence–type
systems, with nanotechnology, and even
with nano-intelligence systems, allowing
clinicians to harvest information and
deliver tailored therapeutics based on
what’s happening in the serum, plasma,
and tissue of any given patient who visits
the doctor. “It’s really going to revolution-
ize the way in which molecular medicine
is performed,” says Petricoin. “It’s going
to happen.”
Ernie Hood
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